News

Danaher completes $5.7 billion acquisition of Abcam

Medical tools supplier Danaher said on Wednesday it has completed the $5.7 billion acquisition of Abcam , overcoming the initial opposition from the founder of the protein consumables maker.

12/06/2023

Exlusive: Why Abcam founder believes Danaher's acquisition offer falls short

In an exclusive interview with Thomas Warner (TW) of Proactive London, Dr Jonathan Milner (JM), the founder of life sciences company Abcam PLC (NASDAQ:ABCM), discusses why he believes the $24 per share acquisition offer from Danaher (NYSE:DHR) severely undervalues the company. Milner criticises the timing of the deal and advises shareholders to consider whether the $5.7 billion acquisition is in their best interest.

10/16/2023

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

What is Abcam plc's stock price?

The price of Abcam plc (ABCM) is 23.99 and it was updated on 2024-04-27 02:29:50.

Is Abcam plc (ABCM) overvalued or undervalued?

Currently Abcam plc (ABCM) is in undervalued.

News

From:

To:

News
GMED or ABCM: Which Is the Better Value Stock Right Now? Investors looking for stocks in the Medical - Instruments sector might want to consider either Globus Medical (GMED) or Abcam PLC Sponsored ADR (ABCM). But which of these two stocks offers value investors a better bang for their buck right now? Thu, Oct. 05, 2023
Danaher Buys Abcam for $5.7 Billion to Expand Its Product Offerings Medical tool supplier Danaher (DHR) is expanding its product offerings by purchasing British biotech firm Abcam Plc (ABCM) for $5.7 billion, including debt. Mon, Aug. 28, 2023
Danaher acquires biotech supplier Abcam for $5.7B Danaher (NYSE:DHR) said it will be acquiring UK-based biotechnology supplier Abcam (AIM:ABC) for $24 per share or a total enterprise value of about $5.7 billion. Danaher (NYSE:DHR) beat out rivals who were also bidding for the company including Agilent Technologies (NYSE:A), according to media reports. Mon, Aug. 28, 2023
Medical tech firm Danaher to buy Abcam in deal valued at $5.7 bln Danaher Corp said on Monday it would buy smaller rival Abcam Plc in a deal valued at $5.7 billion including debt, as the medical tools supplier eyes bigger contracts by expanding its services. Mon, Aug. 28, 2023
Danaher to Buy Abcam in $5.7 Billion Deal. Investors Don't Like the Premium. The industrial scientific-supplies company agrees to acquire all shares outstanding for $24.00 each. Mon, Aug. 28, 2023

Transcripts

Transcipts Data
Abcam plc (ABCM) on Q4 2022 Results - Earnings Call Transcript SA Transcripts Mon, Sep. 12, 2022
Abcam plc (ABCM) on Q4 2021 Results - Earnings Call Transcript SA Transcripts Mon, Mar. 14, 2022

SEC Filings

SEC Filings
Abcam plc (ABCM) - SC 13G/A SEC Filings 02/12/2024
Abcam plc (ABCM) - SC 13G/A SEC Filings 01/12/2024
Abcam plc (ABCM) - 15-12G SEC Filings 12/18/2023
Abcam plc (ABCM) - S-8 POS SEC Filings 12/15/2023
Abcam plc (ABCM) - POSASR SEC Filings 12/15/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 12/08/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 12/06/2023
Abcam plc (ABCM) - 25-NSE SEC Filings 12/06/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 12/04/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 11/20/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 11/17/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 11/06/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 11/01/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 10/23/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 10/23/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 10/17/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 10/16/2023
Abcam plc (ABCM) - SC 13D SEC Filings 10/16/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 10/12/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 10/12/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 10/10/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 10/05/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 09/28/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 09/15/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 09/14/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 08/31/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 08/28/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 08/16/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 07/12/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 07/05/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 06/28/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 06/27/2023
Abcam plc (ABCM) - 6-K/A - Current report SEC Filings 06/27/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 06/26/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 06/23/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 06/23/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 06/21/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 06/20/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 06/20/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 06/16/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 06/12/2023
Abcam plc (ABCM) - SC 13G/A SEC Filings 06/08/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 06/06/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 06/05/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 05/30/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 05/30/2023
Abcam plc (ABCM) - SC 13D/A SEC Filings 05/18/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 05/17/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 05/04/2023
Abcam plc (ABCM) - SC 13D SEC Filings 05/01/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 04/13/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 03/30/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 03/20/2023
Abcam plc (ABCM) - 20-F SEC Filings 03/20/2023
Abcam plc (ABCM) - SC 13G SEC Filings 03/10/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 03/10/2023
Abcam plc (ABCM) - SC 13G/A SEC Filings 02/14/2023
Abcam plc (ABCM) - SC 13G/A SEC Filings 02/10/2023
Abcam plc (ABCM) - SC 13G/A SEC Filings 02/06/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 01/30/2023
Abcam plc (ABCM) - SC 13G SEC Filings 01/18/2023
Abcam plc (ABCM) - 6-K - Current report SEC Filings 12/12/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 11/14/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 10/17/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 09/12/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 08/17/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 07/20/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 05/18/2022
Abcam plc (ABCM) - 20-F/A SEC Filings 04/08/2022
Abcam plc (ABCM) - S-8 SEC Filings 03/29/2022
Abcam plc (ABCM) - F-3ASR SEC Filings 03/29/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 03/17/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 03/14/2022
Abcam plc (ABCM) - 20-F SEC Filings 03/14/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 02/28/2022
Abcam plc (ABCM) - SC 13G SEC Filings 02/14/2022
Abcam plc (ABCM) - SC 13G/A SEC Filings 02/07/2022
Abcam plc (ABCM) - SC 13G SEC Filings 02/04/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 01/27/2022
Abcam plc (ABCM) - 6-K - Current report SEC Filings 12/03/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 11/12/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 10/27/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 09/13/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 09/01/2021
Abcam plc (ABCM) - 20-F SEC Filings 09/01/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 08/13/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 08/02/2021
Abcam plc (ABCM) - S-8 SEC Filings 07/14/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 07/01/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 06/02/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 05/19/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 03/12/2021
Abcam plc (ABCM) - 6-K/A - Current report SEC Filings 03/11/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 03/10/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 03/08/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 02/26/2021
Abcam plc (ABCM) - SC 13G SEC Filings 02/12/2021
Abcam plc (ABCM) - S-8 SEC Filings 01/28/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 01/28/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 01/11/2021
Abcam plc (ABCM) - 6-K - Current report SEC Filings 12/22/2020
Abcam plc (ABCM) - 6-K - Current report SEC Filings 12/07/2020
Abcam plc (ABCM) - 6-K - Current report SEC Filings 11/04/2020
Abcam plc (ABCM) - 6-K - Current report SEC Filings 11/03/2020
Abcam plc (ABCM) - EFFECT SEC Filings 10/22/2020
Abcam plc (ABCM) - 424B4 SEC Filings 10/22/2020
Abcam plc (ABCM) - EFFECT SEC Filings 10/21/2020
Abcam plc (ABCM) - UPLOAD SEC Filings 10/21/2020
Abcam plc (ABCM) - F-1MEF SEC Filings 10/21/2020
Abcam plc (ABCM) - F-1/A SEC Filings 10/21/2020
Abcam plc (ABCM) - CORRESP SEC Filings 10/21/2020
Abcam plc (ABCM) - CERT SEC Filings 10/21/2020
Abcam plc (ABCM) - F-1/A SEC Filings 10/19/2020
Abcam plc (ABCM) - CORRESP SEC Filings 10/19/2020
Abcam plc (ABCM) - 8-A12B SEC Filings 10/19/2020
Abcam plc (ABCM) - F-1 SEC Filings 10/02/2020
Abcam plc (ABCM) - CORRESP SEC Filings 10/02/2020
Abcam plc (ABCM) - UPLOAD SEC Filings 09/29/2020
Abcam plc (ABCM) - DRSLTR SEC Filings 09/16/2020
Abcam plc (ABCM) - DRS/A SEC Filings 09/16/2020
Abcam plc (ABCM) - UPLOAD SEC Filings 09/15/2020
Abcam plc (ABCM) - DRSLTR SEC Filings 08/28/2020
Abcam plc (ABCM) - DRS/A SEC Filings 08/28/2020
Abcam plc (ABCM) - UPLOAD SEC Filings 08/24/2020
Abcam plc (ABCM) - DRSLTR SEC Filings 07/23/2020
Abcam plc (ABCM) - DRS SEC Filings 07/23/2020
Abcam plc (ABCM) - D SEC Filings 03/12/2020
Abcam plc (ABCM) - F-6 POS SEC Filings 09/29/2017
Abcam plc (ABCM) - F-6EF SEC Filings 11/06/2014
Abcam plc (ABCM) - D SEC Filings 04/27/2012
Abcam plc (ABCM) - F-6EF SEC Filings 12/16/2011
Abcam plc (ABCM) - F-6EF SEC Filings 08/30/2011
Abcam plc (ABCM) - D SEC Filings 06/08/2011
Abcam plc (ABCM) - F-6EF SEC Filings 05/17/2010

Press Releases

StockPrice Release
Danaher completes acquisition of abcam 12/06/2023
Acquisition of abcam by danaher approved by the high court of justice of england and wales 12/04/2023
Statement from dr. jonathan milner on the suspension of the “vote against” campaign 11/01/2023
Jonathan milner issues statement responding to the glass lewis report 10/23/2023
Jonathan milner issues statement responding to iss report 10/16/2023
Jonathan milner releases presentation to abcam plc shareholders, outlining reasons to reject danaher's bid and strategic vision for the company 10/16/2023
Abcam investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of abcam plc - abcm 10/10/2023
Jonathan milner issues open letter to shareholders of abcam plc 10/10/2023
Jonathan milner issues open letter to shareholders of abcam plc 09/28/2023
Abcam plc statement on dr. jonathan milner's announcement 09/14/2023
Dr. jonathan milner opposes danaher's acquisition of abcam and calls for egm to replace board 09/14/2023
Abcam plc interim results for the six-month period ended 30 june 2023 08/31/2023
Abcam investor alert by the former attorney general of louisiana: kahn swick & foti, llc investigates adequacy of price and process in proposed sale of abcam plc - abcm 08/29/2023
Abcm stock alert: halper sadeh llc is investigating whether the sale of abcam plc is fair to shareholders 08/28/2023
Danaher to acquire abcam for $24.00 per share 08/28/2023
Danaher to acquire abcam 08/28/2023
Abcam plc: all resolutions withdrawn at abcam's egm 07/12/2023
Abcam plc: trading update 07/05/2023
Abcam confirms dr. jonathan milner has withdrawn egm requisition notice and related resolutions 06/28/2023
Starboard issues statement regarding the opportunity to maximize value at abcam 06/26/2023
Abcam plc: fy2024 guidance 06/26/2023
Abcam announces review of strategic alternatives 06/23/2023
Jonathan milner issues open letter to shareholders of abcam plc 06/23/2023
Jonathan milner issues open letter to shareholders of abcam plc 06/21/2023
Abcam highlights successful execution of strategic priorities to drive shareholder value 06/20/2023
Abcam plc files and mails shareholder circular calling an extraordinary general meeting 06/16/2023
Jonathan milner issues open letter to shareholders of abcam plc 06/12/2023
Abcam plc: statement on calling an extraordinary general meeting 05/30/2023
Jonathan milner calls extraordinary general meeting to restore focus to abcam on governance, execution, and cost control 05/30/2023
Abcam plc result of annual general meeting 05/17/2023
Jonathan milner announces that he is taking steps to call an extraordinary general meeting of abcam shareholders 05/17/2023
Abcam, plc business update 05/04/2023
Abcam plc comments on investor engagement 05/01/2023
Abcam plc: upcoming abcam investor events 04/17/2023
Abcam plc: trading update 04/13/2023
Lunaphore and abcam announce agreement for primary antibody validation for use on comet™, combining power of trusted antibody provider with superior multiplex capabilities 04/06/2023
Abcam plc: final results for the year ended 31 december 2022 03/20/2023
Abcam to report full year results on monday, march 20, 2023 03/10/2023
Abcam plc: update on aim delisting 12/12/2022
Abcam plc: result of general meeting - shareholders approve aim delisting 11/11/2022
Nanostring and abcam expand collaboration to advance spatial multiomics research 11/09/2022
Abcam plc: proposed resolution for cancellation of aim listing 10/17/2022
Abcam plc: interim results for the six-month period ended 30 june 2022 09/12/2022
Abcam plc first half trading update 07/20/2022
Abcam: appointment of vice president of investor relations 06/27/2022
Abcam the most awarded company at 2022 industry awards 03/25/2022
Abcam plc results for the 12- and 18-month periods ended 31 december 2021 03/14/2022
Abcam collaborates with twist bioscience to enhance antibody discovery for diagnostic and research applications 02/01/2022
Alamar biosciences partners with abcam to drive understanding of the human proteome 01/04/2022
Abcam completes $340m strategic acquisition and expands kit capacity and capability 10/27/2021
Abcam to acquire biovision for $340 million 08/02/2021
Abcam opens new us facility in boston, ma 07/13/2021
Pionyr and abcam extend partnership to evaluate trem2-expressing cells in cancer patients 06/22/2021
Abcam and medx extend precision medicine strategic partnership 04/12/2021
Avacta announces distribution agreement with abcam plc 04/06/2021
Abcam wins industry awards from citeab 03/24/2021
8.3% constant currency revenue growth in h1 as customers gradually return to labs 03/08/2021
Abcam expands presence in china to support increased demand of biopharma sector 03/04/2021
Abcam to report interim results on monday, march 8, 2021 02/26/2021
Abcam to present at the 2021 svb leerink global healthcare conference 02/17/2021
Abingdon health signs collaboration and co-marketing agreement with abcam 02/09/2021
Abcam plc appointment of non-executive directors 01/28/2021

More Headlines

News
Abcam agrees to be acquired by Danaher in $5.7B deal Abcam Plc stock ABCM, +3.87% was up 0.4% in premarket trades Monday after it said it agreed to be acquired by Danaher Corp. DHR, +0.78% for $24 a share in cash in a deal that values the maker of antibodies and reagents for drug discovery efforts at about $5.7 billion including debt. The price amounts to a premium of 64 cents a share, or 2.7% over its closing price of $23.36 on Friday. 08/28/2023
Exclusive: Danaher in the lead to acquire biomedical equipment vendor Abcam-sources Danaher Corp is in the lead to acquire Abcam Plc , a provider of supplies to life science researchers with a market value of $5.1 billion, as it expands its biomedical offerings, people familiar with the matter said on Friday. 08/25/2023
Why Shares of Abcam Are Jumping Friday Abcam specializes in products, such as assays or reagents, used in biologic drug discovery. The company saw revenue grow but reported a loss in 2022. 06/23/2023
Are You Looking for a Top Momentum Pick? Why Abcam PLC Sponsored ADR (ABCM) is a Great Choice Does Abcam PLC Sponsored ADR (ABCM) have what it takes to be a top stock pick for momentum investors? Let's find out. 06/21/2023
3 Stocks With Upgraded Broker Ratings for Robust Returns As brokers have a deeper insight into stocks, one must follow rating upgrades for solid returns. We choose Abcam (ABCM), Maxeon Solar (MAXN) and Allegiant Travel (ALGT) as these witness rating upgrades. 06/21/2023
Is Abcam (ABCM) Outperforming Other Medical Stocks This Year? Here is how Abcam PLC Sponsored ADR (ABCM) and Apyx Medical (APYX) have performed compared to their sector so far this year. 06/20/2023
Why Shares in Abcam Surged This Week Abcam operates in some highly attractive end markets, but its operational execution is not what it should be, according to its funder and former director. Dr. Jonathan Milner has called for the removal of three board members and his appointment as executive chairman. 06/15/2023
Abcam: Nosebleed Valuations, Flat Growth Profile Justify Hold Rating Abcam plc's outlook remains unchanged after a mixed FY'22, with improvements needed in fundamental, sentiment, and valuation factors to attract buyers. Despite a strong FY'22, ABCM's poor returns on capital, economic losses and flat growth outlook hinder its investment potential. The company needs to enhance performance across key metrics to create value for shareholders and warrant a buy rating. 06/09/2023
How Much Upside is Left in Abcam PLC Sponsored ADR (ABCM)? Wall Street Analysts Think 27.55% The mean of analysts' price targets for Abcam PLC Sponsored ADR (ABCM) points to a 27.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. 05/23/2023
Abcam plc (ABCM) Q4 2022 Earnings Call Transcript State Bank of India ADR (NASDAQ:ABCM ) Q4 2022 Earnings Conference Call March 20, 2023 8:00 AM ET Company Participants Tommy Thomas - Vice President of Investor Relations Alan Hirzel - Chief Executive Officer Michael Baldock - Chief Financial Officer Conference Call Participants Tejas Sevant - Morgan Stanley Puneet Souda - SBV Securities Matt Larew - William Blair Michael Ryskin - Bank of America Charles Weston - RBC Justin Bowers - Deutsche Bank Operator Hello, and welcome to the Abcam plc Full-Year 2022 Earnings Conference Call. My name is Alex, I'll be coordinating the call today. 03/20/2023
Abcam to Report Full Year Results on Monday, March 20, 2023 CAMBRIDGE, England and WALTHAM, Mass. , March 10, 2023 /PRNewswire/ -- Abcam plc (Nasdaq: ABCM) ("Abcam" or the "Company"), a global leader in the supply of life science research tools, will report its results for the year ended 31 December 2022 at 7.00 a.m. 03/10/2023
Abcam: A Good Growth Stock In The Healthcare Market I will update my previously published article on Abcam from 15 months ago. Readers will have the opportunity to learn about interim events with the company. 09/29/2022
Abcam plc (ABCM) Q4 2022 Earnings Call Transcript Abcam plc (NASDAQ:ABCM ) Q4 2022 Results Conference Call September 12, 2022 8:00 AM ET Company Participants Tommy Thomas - IR Alan Hirzel - CEO Michael Baldock - CFO Conference Call Participants Tejas Savant - Morgan Stanley Charles Weston - RBC Puneet Souda - SBV Securities Matt Larew - William Blair Michael Ryskin - Bank of America. Operator Ladies and gentlemen, welcome to the Abcam Interim Results Webcast for the period ending June 30, 2022. 09/12/2022
Abcam (ABCM) CEO, Alan Hirzel on Q4 2021 Results - Earnings Call Transcript Abcam (ABCM) CEO, Alan Hirzel on Q4 2021 Results - Earnings Call Transcript 03/14/2022
4 High Financial Strength Stocks Trading Near Historical Low Price-Book Ratios According to the Historical Low Price-Book Screen, a Premium feature of GuruFocus, four stocks with high financial strength and are trading near historical low price-book ratios are Landstar System Inc. ( LSTR , Financial), 51job Inc. ( JOBS , Financial), Abcam PLC ( ABCM , Financial) and SAP SE ( SAP , Financial). 09/15/2021
Abcam jumps as it snaps up major supplier BioVision Abcam PLC shares rose on Monday as the research tools maker said it had struck a deal to acquire BioVision Inc, a subsidiary of chemicals firm Chinese firm NKY Medical Holdings, for US$340mln in cash. BioVision distributes research tools and has a strength in the assay kits market, Abcam said, adding that the purchase will bring one of its large third-party suppliers in-house. 08/02/2021
Abcam To Acquire Supplier BioVision For $340M In Cash Abcam plc (NASDAQ: ABCM) has agreed to acquire BioVision Inc, a wholly-owned Boai NKY Medical Holdings Ltd subsidiary, for $340 million in cash. The Milpitas, California-based BioVision is a distributor of life science research tools to biopharma, diagnostic and academic customers, with strength in biochemical and cell-based assay kits. 08/02/2021
Abcam to Acquire BioVision for $340 million CAMBRIDGE, United Kingdom, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM LSE: ABC; Nasdaq: ABCM) ("Abcam", “the Company” or "the Group"), a global leader in the supply of life science research tools, today announces that it has entered into a definitive agreement to acquire BioVision, Inc. ("BioVision"), a wholly owned subsidiary of Boai NKY Medical Holdings Ltd. (“NKY”), for $340 million (the “Acquisition”). 08/02/2021
New Strong Sell Stocks for July 29th ABCM, CCJ, EBMT, MRTN and NESR have been added to the Zacks Rank #5 (Strong Sell) List on July 29, 2021. 07/29/2021
Proteomics International engages Abcam to manufacture PromarkerD reagents Proteomics International Laboratories Ltd (ASX:PIQ) has engaged global life science company Abcam plc (LON:ABC) (OTCMKTS:ABCZF) to manufacture reagents for the immunoassay version of its PromarkerD predictive blood test for the early detection of kidney disease in patients with type 2 diabetes. Abcam is a leader in the supply of life science research tools and reagents, including supply to those companies developing and marketing diagnostic solutions around the world. 07/22/2021
Abcam opens new US facility in Boston, MA CAMBRIDGE, July 13, 2021 /PRNewswire/ -- Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life sciences reagents and tools, today announces the opening of a major new site in Waltham, MA. The new facility is a central component of Abcam's growth in the United States, reinforcing its commitment to support the research and biopharma sector globally and serving as a hub for the Company's R&D and commercial activities in the region. 07/13/2021
Abcam: A Promising Business Model In The Drug Industry I will outline the history of drug development. Information for the Abcam business model will be outlined for my readers. 07/09/2021
Pionyr and Abcam extend partnership to evaluate TREM2-expressing cells in cancer patients SOUTH SAN FRANCISCO, Calif. and CAMBRIDGE, England, June 22, 2021 /PRNewswire/ -- Today Pionyr Immunotherapeutics, Inc., a company developing first-in-class antibody therapeutics that increase the body's anti-tumor immunity and Abcam (AIM: ABC) (NASDAQ: ABCM), a global innovator in life science reagents and tools, announced the extension of their collaboration with a new commercial licensing agreement to support the progression of PY314, the first to the clinic of Pionyr's compounds. 06/22/2021
Abcam and MEDx extend precision medicine strategic partnership CAMBRIDGE, United Kingdom and SHANGHAI, China, April 12, 2021 (GLOBE NEWSWIRE) -- Abcam (AIM: ABC; NASDAQ: ABCM), a global innovator in life science reagents and tools, and MEDx Translational Medicine (MEDx), formerly QIAGEN (Suzhou) Translational Medicine Co., Ltd., a company dedicated to developing companion diagnostics and precision medicine, announced the extension of their strategic partnership to include the co-development and commercialization of key companion and in vitro diagnostic kits for MEDx to supply to the Chinese market. 04/12/2021
Avacta Announces Distribution Agreement With ABCAM plc CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre\|CISION™ platforms, is pleased to announce that it has entered into a global distribution agreement with ABCAM plc (AIM: ABC; NASDAQ: ABCM) to sell the Group's recently developed SARS-CoV-2 research ELISA Affimer® reagents. Avacta has developed Affimer® reagents which can be used in a high performance ELISA laboratory test to de 04/06/2021
5 Companies Trading Below Historical Low Price-Book as of March Stocks with high business profitability and price-book ratios near 10-year lows 03/26/2021
Abcam Wins Industry Awards from CiteAb CAMBRIDGE, United Kingdom, March 24, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced that Dr Alejandra Solache, SVP of Research & Development received the CiteAb award for ‘Significant Individual Impact' and the Company was recognized as ‘Antibody Supplier Succeeding in Cardiovascular Research'. 03/24/2021
Abcam (ABCZF) CEO, Alan Hirzel on 2021 Interim Results - Earnings Call Transcript Abcam (ABCZF) CEO, Alan Hirzel on 2021 Interim Results - Earnings Call Transcript 03/08/2021
8.3% constant currency revenue growth in H1 as customers gradually return to labs CAMBRIDGE, United Kingdom, March 08, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; AIM: ABC) (“Abcam”, the “Group” or the “Company”), a global leader in the supply of life science research tools, today announces its interim results for the six month period ended 31 December 2020 (“H1 2021”). 03/08/2021
Abcam Expands Presence in China to Support Increased Demand of BioPharma Sector CAMBRIDGE, United Kingdom, March 04, 2021 (GLOBE NEWSWIRE) -- Today Abcam (AIM:ABC; NASDAQ:ABCM), a global innovator in life science reagents and tools, announced the expansion of its footprint in China with the opening of new custom-built facilities in Hangzhou and Shanghai. Expanded customer service, logistics and manufacturing capabilities are strengthening Abcam's position as a leading collaborator for academia and industry in the region. 03/04/2021
Abcam to Report Interim Results on Monday, March 8, 2021 CAMBRIDGE, United Kingdom, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam” or the “Company”), a global leader in the supply of life science research tools, will report its Interim Results for the six-month period ended 31 December 2020 at 12.00 p.m. GMT (7.00 a.m. EST) on Monday, March 8, 2021. 02/26/2021
Abcam to present at the 2021 SVB Leerink Global Healthcare Conference CAMBRIDGE, United Kingdom, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Abcam plc (Nasdaq: ABCM; LSE: ABC) today announced that Alan Hirzel, Chief Executive Officer, will present at the 2021 SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8.00 EST / 13.00 GMT. A live webcast of the presentation can be accessed via the IR Calendar page of Abcam's Investor Relations website at https://www.abcamplc.com/reports-presentations. 02/17/2021
Abcam Plc Appointment of Non-Executive Directors CAMBRIDGE, United Kingdom, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Abcam plc (AIM: ABC; Nasdaq: ABCM) (“Abcam”), a global leader in the supply of life science research tools, is delighted to announce the appointments of Bessie Lee and Mark Capone as non-executive Directors with immediate effect. 01/28/2021
Abcam: An Attractive, Profitable Medtech But Pricy Abcam has a strong position in the niche of supplies for antibody research. It is profitable, dividend paying, and continues to grow well. 01/18/2021

Unlock

ABCM Ratings Summary

ABCM Quant Ranking